The post Ethereum stalls at $3,063 – Bounce or bull trap ahead? appeared on BitcoinEthereumNews.com. Journalist Posted: November 30, 2025 Ethereum has rallied 14% since the low at $2,623 that it registered on the 21st of November. While this was a respectable bounce, it has been curtailed by the resistance at $3,063. This level was an important lower timeframe swing level. Source: CryptoQuant Based on the large holder balances metric, we see that the 10k-100k ETH holding whale cohort has been accumulating since June. This was when the Ethereum digital asset treasury idea really took off, with Bitmine Immersion [BMNR] leading the way. It was not all accumulation. As the chart showed, the 100-10k holders have been selling in recent months, reflecting a lack of long-term confidence. AMBCrypto’s report captured how the Ethereum [ETH] exchange-traded funds (ETFs) saw a surge in inflows over the past week, but it was not enough to outweigh the rest of November’s outflows. Should traders and investors expect a recovery next, or will the current downtrend resume at the psychological $3k resistance? Ethereum could continue its gains next week Source: ETH/USDT on TradingView On the weekly chart, the uptrend remained intact despite the deep retracement from $4.9k to $2.6k. The swing points (orange) showed that a weekly move below $2.1k is required to flip the structure bearishly. Source: ETH/USDT on TradingView The structure on the 4-hour chart was bearish, despite the rally since the 21st of November. An attempted move past $3,063 met with a minor price dip. The low trading volume and lack of buying pressure on the OBV indicated that buyers were not strong enough to drive a rally now. However, the rejection from this resistance wasn’t brutal and quick. This could be an early sign of acceptance and fading short-term sell pressure. A move past $3,063 and a retest as support would offer a buying opportunity. The… The post Ethereum stalls at $3,063 – Bounce or bull trap ahead? appeared on BitcoinEthereumNews.com. Journalist Posted: November 30, 2025 Ethereum has rallied 14% since the low at $2,623 that it registered on the 21st of November. While this was a respectable bounce, it has been curtailed by the resistance at $3,063. This level was an important lower timeframe swing level. Source: CryptoQuant Based on the large holder balances metric, we see that the 10k-100k ETH holding whale cohort has been accumulating since June. This was when the Ethereum digital asset treasury idea really took off, with Bitmine Immersion [BMNR] leading the way. It was not all accumulation. As the chart showed, the 100-10k holders have been selling in recent months, reflecting a lack of long-term confidence. AMBCrypto’s report captured how the Ethereum [ETH] exchange-traded funds (ETFs) saw a surge in inflows over the past week, but it was not enough to outweigh the rest of November’s outflows. Should traders and investors expect a recovery next, or will the current downtrend resume at the psychological $3k resistance? Ethereum could continue its gains next week Source: ETH/USDT on TradingView On the weekly chart, the uptrend remained intact despite the deep retracement from $4.9k to $2.6k. The swing points (orange) showed that a weekly move below $2.1k is required to flip the structure bearishly. Source: ETH/USDT on TradingView The structure on the 4-hour chart was bearish, despite the rally since the 21st of November. An attempted move past $3,063 met with a minor price dip. The low trading volume and lack of buying pressure on the OBV indicated that buyers were not strong enough to drive a rally now. However, the rejection from this resistance wasn’t brutal and quick. This could be an early sign of acceptance and fading short-term sell pressure. A move past $3,063 and a retest as support would offer a buying opportunity. The…

Ethereum stalls at $3,063 – Bounce or bull trap ahead?

Ethereum has rallied 14% since the low at $2,623 that it registered on the 21st of November. While this was a respectable bounce, it has been curtailed by the resistance at $3,063.

This level was an important lower timeframe swing level.

Source: CryptoQuant

Based on the large holder balances metric, we see that the 10k-100k ETH holding whale cohort has been accumulating since June.

This was when the Ethereum digital asset treasury idea really took off, with Bitmine Immersion [BMNR] leading the way.

It was not all accumulation. As the chart showed, the 100-10k holders have been selling in recent months, reflecting a lack of long-term confidence.

AMBCrypto’s report captured how the Ethereum [ETH] exchange-traded funds (ETFs) saw a surge in inflows over the past week, but it was not enough to outweigh the rest of November’s outflows.

Should traders and investors expect a recovery next, or will the current downtrend resume at the psychological $3k resistance?

Ethereum could continue its gains next week

Source: ETH/USDT on TradingView

On the weekly chart, the uptrend remained intact despite the deep retracement from $4.9k to $2.6k. The swing points (orange) showed that a weekly move below $2.1k is required to flip the structure bearishly.

Source: ETH/USDT on TradingView

The structure on the 4-hour chart was bearish, despite the rally since the 21st of November. An attempted move past $3,063 met with a minor price dip.

The low trading volume and lack of buying pressure on the OBV indicated that buyers were not strong enough to drive a rally now.

However, the rejection from this resistance wasn’t brutal and quick. This could be an early sign of acceptance and fading short-term sell pressure.

A move past $3,063 and a retest as support would offer a buying opportunity. The target would be the $3.4k supply zone.

Highlighted in red, this area was important on the 1-day timeframe, where the trend has been bearish since late September.


Final Thoughts

  • A move past $3,063 would likely present traders with a buying opportunity targeting the supply zone around $3.5k.
  • Even though the weekly chart is bullish, Ethereum will have a hard time surpassing the resistance at $3.5k, making it a good take-profit level for bulls who bought the recent bounce.

Disclaimer: The information presented does not constitute financial, investment, trading, or other types of advice and is solely the writer’s opinion

Next: Big money won’t stop buying Bitcoin! Corporate treasuries now own 1 mln BTC

Source: https://ambcrypto.com/ethereum-stalls-at-3063-bounce-or-bull-trap-ahead/

Market Opportunity
Ethereum Logo
Ethereum Price(ETH)
$3,305.39
$3,305.39$3,305.39
-0.78%
USD
Ethereum (ETH) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26